Oncodermatology in Practice: Managing Immune Checkpoint Inhibitor Skin Toxicities

Immune checkpoint inhibitors can cause a broad spectrum of cutaneous toxicities, ranging from mild eruptions to severe inflammatory, autoimmune, and blistering disorders. This session focuses on practical oncodermatology management, including grading toxicity, selecting topical or systemic treatment, determining when therapy can continue, and recognizing when urgent oncology coordination is needed. The goal is to support effective cancer treatment while minimizing dermatologic morbidity.